23 results on '"Cassina, Laura"'
Search Results
2. Fibrocystin/Polyductin releases a C-terminal fragment that translocates into mitochondria and suppresses cystogenesis
- Author
-
Walker, Rebecca V, Yao, Qin, Xu, Hangxue, Maranto, Anthony, Swaney, Kristen F, Ramachandran, Sreekumar, Li, Rong, Cassina, Laura, Polster, Brian M, Outeda, Patricia, Boletta, Alessandra, Watnick, Terry, and Qian, Feng
- Published
- 2023
- Full Text
- View/download PDF
3. Primary cilia sense glutamine availability and respond via asparagine synthetase
- Author
-
Steidl, Maria Elena, Nigro, Elisa A., Nielsen, Anne Kallehauge, Pagliarini, Roberto, Cassina, Laura, Lampis, Matteo, Podrini, Christine, Chiaravalli, Marco, Mannella, Valeria, Distefano, Gianfranco, Yang, Ming, Aslanyan, Mariam, Musco, Giovanna, Roepman, Ronald, Frezza, Christian, and Boletta, Alessandra
- Published
- 2023
- Full Text
- View/download PDF
4. Disruption of polycystin-1 cleavage leads to cardiac metabolic rewiring in mice
- Author
-
Amaral, Andressa G., da Silva, Camille C.C., Serna, Julian D.C., Honorato-Sampaio, Kinulpe, Freitas, Jéssica A., Duarte-Neto, Amaro N., Bloise, Antonio C., Cassina, Laura, Yoshinaga, Marcos Y., Chaves-Filho, Adriano B., Qian, Feng, Miyamoto, Sayuri, Boletta, Alessandra, Bordin, Silvana, Kowaltowski, Alicia J., and Onuchic, Luiz F.
- Published
- 2022
- Full Text
- View/download PDF
5. Metabolic reprogramming in polycystic kidney disease explained by super-enhancers and CDK7: new therapeutic targets?
- Author
-
Cassina, Laura and Boletta, Alessandra
- Published
- 2020
- Full Text
- View/download PDF
6. Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC‐driven lymphoma.
- Author
-
Donati, Giulio, Nicoli, Paola, Verrecchia, Alessandro, Vallelonga, Veronica, Croci, Ottavio, Rodighiero, Simona, Audano, Matteo, Cassina, Laura, Ghsein, Aya, Binelli, Giorgio, Boletta, Alessandra, Mitro, Nico, and Amati, Bruno
- Abstract
MYC is a key oncogenic driver in multiple tumor types, but concomitantly endows cancer cells with a series of vulnerabilities that provide opportunities for targeted pharmacological intervention. For example, drugs that suppress mitochondrial respiration selectively kill MYC‐overexpressing cells. Here, we unravel the mechanistic basis for this synthetic lethal interaction and exploit it to improve the anticancer effects of the respiratory complex I inhibitor IACS‐010759. In a B‐lymphoid cell line, ectopic MYC activity and treatment with IACS‐010759 added up to induce oxidative stress, with consequent depletion of reduced glutathione and lethal disruption of redox homeostasis. This effect could be enhanced either with inhibitors of NADPH production through the pentose phosphate pathway, or with ascorbate (vitamin C), known to act as a pro‐oxidant at high doses. In these conditions, ascorbate synergized with IACS‐010759 to kill MYC‐overexpressing cells in vitro and reinforced its therapeutic action against human B‐cell lymphoma xenografts. Hence, complex I inhibition and high‐dose ascorbate might improve the outcome of patients affected by high‐grade lymphomas and potentially other MYC‐driven cancers. Synopsis: Deregulated expression of the oncogenic transcription factor MYC in B‐cell lymphoma induces a vulnerability to disruption of redox homeostasis by pharmacological treatment with the electron transport chain (ETC) complex I inhibitor IACS‐010759 and high‐dose ascorbate. MYC activation and IACS‐010759 treatment independently cause the buildup of reactive oxygen species (ROS), contributing to their synthetic‐lethal action in B‐cells.Glucose prevents IACS‐010759‐induced cell killing by sustaining the pentose phosphate pathway (PPP)‐dependent production of NADPH, which is then used to regenerate reduced glutathione (GSH), a major cellular antioxidant.High‐dose ascorbate augments IACS‐010759‐induced cell killing through an iron‐dependent pro‐oxidant activity.High‐dose ascorbate and IACS‐010759 show synergistic anti‐tumoral activity in pre‐clinical models of MYC‐driven B‐cell lymphomas. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. A novel truncated form of eNOS associates with altered vascular function
- Author
-
Galluccio, Elena, Cassina, Laura, Russo, Isabella, Gelmini, Fabrizio, Setola, Emanuela, Rampoldi, Luca, Citterio, Lorena, Rossodivita, Alessandra, Kamami, Mikel, Colombo, Antonio, Alfieri, Ottavio, Carini, Marina, Bosi, Emanuele, Trovati, Mariella, Piatti, PierMarco, Monti, Lucilla D., and Casari, Giorgio
- Published
- 2014
- Full Text
- View/download PDF
8. Hyperinsulinemia and impaired leptin-adiponectin ratio associate with endothelial nitric oxide synthase polymorphisms in subjects with in-stent restenosis
- Author
-
Galluccio, Elena, Piatti, PierMarco, Citterio, Lorena, Lucotti, Pietro C.G., Setola, Emanuela, Cassina, Laura, Oldani, Matteo, Zavaroni, Ivana, Bosi, Emanuele, Colombo, Antonio, Alfieri, Ottavio, Casari, Giorgio, Reaven, Gerald M., and Monti, Lucilla D.
- Subjects
Metabolic diseases -- Research ,Leptin -- Properties ,Genetic polymorphisms -- Health aspects ,Type 2 diabetes -- Research ,Nitric oxide -- Genetic aspects ,Nitric oxide -- Health aspects ,Biological sciences - Abstract
Little is known about the association of endothelial nitric oxide synthase (NOS3) gene polymorphisms and the presence of insulin resistance and the early evolution of atherosclerosis in nondiabetic subjects with cardiovascular disease (CAD) and stent implantation. The present study was performed in an attempt to better understand whether metabolic, endothelial, and angiographic findings characteristic of subjects with cardiovascular disease and in-stent restenosis are related to NOS3 variants. This is a case-control study performed from 2002 to 2006. All subjects admitted to the study were recruited in the Nord-Centre of Italy, most from Milan and its surrounding towns. Measures of glucose tolerance, insulin sensitivity, markers of endothelial dysfunction, forearm vasodilation, and adipokine levels were determined and associated to the frequency of two single-nucleotide polymorphisms of NOS3, i.e., [Glu.sup.298]Asp (rs1799983, G/T) and rs753482 (intron 18 A/C). A total of 747 subjects, not known to have diabetes, were evaluated: 333 subjects had asymptomatic CAD, 106 subjects had unstable angina and were evaluated for in-stent restenosis 6 mo after stent placement, and 308 were control subjects. The presence of TT and CC minor alleles was significantly greater in case groups compared with control subjects. At phenotypic level, subjects with the polymorphisms were characterized by hyperinsulinemia and reduced reactive hyperemia, whereas increased leptin and decreased adiponectin levels were present in subjects with restenosis in the presence of reduced minimal lumen diameter and length of stenosis almost doubled. Hyperinsulinemia, endothelial dysfunction, and a more atherogenic profile seem to be peculiar features of subjects with asymptomatic CAD and restenosis carrying NOS3 gene variants. NOS3 gene variants; coronary artery disease; type 2 diabetes
- Published
- 2008
9. Loss of m-AAA protease in mitochondria causes complex I deficiency and increased sensitivity to oxidative stress in hereditary spastic paraplegia
- Author
-
Atorino, Luigia, Silvestri, Laura, Koppen, Mirko, Cassina, Laura, Ballabio, Andrea, Marconi, Roberto, Langer, Thomas, and Casari, Giorgio
- Subjects
Cell research -- Analysis ,Fibroblasts -- Genetic aspects ,Fibroblasts -- Physiological aspects ,Gene mutations -- Physiological aspects ,Mitochondrial membranes -- Genetic aspects ,Mitochondrial membranes -- Physiological aspects ,Pathogenic microorganisms -- Genetic aspects ,Pathogenic microorganisms -- Physiological aspects ,Proteins -- Genetic aspects ,Proteins -- Physiological aspects ,Nervous system -- Causes of ,Nervous system -- Degeneration ,Biological sciences - Abstract
Mutations in paraplegin, a putative mitochondrial metallopeptidase of the AAA family, cause an autosomal recessive form of hereditary spastic paraplegia (HSP). Here, we analyze the function of paraplegin at the cellular level and characterize the phenotypic defects of HSP patients' cells lacking this protein. We demonstrate that paraplegin coassembles with a homologous protein, AFG3L2, in the mitochondrial inner membrane. These two proteins form a high molecular mass complex, which we show to be aberrant in HSP fibroblasts. The loss of this complex causes a reduced complex I activity in mitochondria and an increased sensitivity to oxidant stress, which can both be rescued by exogenous expression of wild-type paraplegin. Furthermore, complementation studies in yeast demonstrate functional conservation of the human paraplegin-AFG3L2 complex with the yeast m-AAA protease and assign proteolytic activity to this structure. These results shed new light on the molecular pathogenesis of HSP and functionally link AFG3L2 to this neurodegenerative disease.
- Published
- 2003
10. Targeting mitochondrial respiration and the BCL2 family in high‐grade MYC‐associated B‐cell lymphoma.
- Author
-
Donati, Giulio, Ravà, Micol, Filipuzzi, Marco, Nicoli, Paola, Cassina, Laura, Verrecchia, Alessandro, Doni, Mirko, Rodighiero, Simona, Parodi, Federica, Boletta, Alessandra, Vellano, Christopher P., Marszalek, Joseph R., Draetta, Giulio F., and Amati, Bruno
- Abstract
Multiple molecular features, such as activation of specific oncogenes (e.g., MYC, BCL2) or a variety of gene expression signatures, have been associated with disease course in diffuse large B‐cell lymphoma (DLBCL), although their relationships and implications for targeted therapy remain to be fully unraveled. We report that MYC activity is closely correlated with—and most likely a driver of—gene signatures related to oxidative phosphorylation (OxPhos) in DLBCL, pointing to OxPhos enzymes, in particular mitochondrial electron transport chain (ETC) complexes, as possible therapeutic targets in high‐grade MYC‐associated lymphomas. In our experiments, indeed, MYC sensitized B cells to the ETC complex I inhibitor IACS‐010759. Mechanistically, IACS‐010759 triggered the integrated stress response (ISR) pathway, driven by the transcription factors ATF4 and CHOP, which engaged the intrinsic apoptosis pathway and lowered the apoptotic threshold in MYC‐overexpressing cells. In line with these findings, the BCL2‐inhibitory compound venetoclax synergized with IACS‐010759 against double‐hit lymphoma (DHL), a high‐grade malignancy with concurrent activation of MYC and BCL2. In BCL2‐negative lymphoma cells, instead, killing by IACS‐010759 was potentiated by the Mcl‐1 inhibitor S63845. Thus, combining an OxPhos inhibitor with select BH3‐mimetic drugs provides a novel therapeutic principle against aggressive, MYC‐associated DLBCL variants. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Respiratory dysfunction by AFG3L2 deficiency causes decreased mitochondrial calcium uptake via organellar network fragmentation
- Author
-
Maltecca, Francesca, De Stefani, Diego, Cassina, Laura, Consolato, Francesco, Wasilewski, Michal, Scorrano, Luca, Rizzuto, Rosario, and Casari, Giorgio
- Published
- 2012
- Full Text
- View/download PDF
12. Targeting the Mitochondrial Protease Clpp Unveils Mitochondrial Vulnerabilities in Multiple Myeloma
- Author
-
Perini, Tommaso, Oliva, Laura, Materozzi, Maria, Del Pizzo, Rossella, Cassina, Laura, Samur, Mehmet K., Orfanelli, Ugo, Milan, Enrico, Boletta, Alessandra, Munshi, Nikhil C, and Cenci, Simone
- Published
- 2022
- Full Text
- View/download PDF
13. Intracellular Iron Overload Induces Metabolic Switching in Active Hematopoietic Stem Cells in Beta-Thalassemia
- Author
-
Aprile, Annamaria, Sighinolfi, Silvia, Cassina, Laura, Panzeri, Mariacarla, Storto, Mariangela, Beretta, Stefano, Merelli, Ivan, Boletta, Alessandra, and Ferrari, Giuliana
- Published
- 2022
- Full Text
- View/download PDF
14. P-111: Targeting the mitochondrial protease ClpP unveils novel vulnerabilities in multiple myeloma
- Author
-
Perini, Tommaso, Materozzi, Maria, Pizzo, Rossella Del, Cassina, Laura, Samur, Mehmet, Orfanelli, Ugo, Milan, Enrico, Boletta, Alessandra, Munshi, Nikhil, and CENCI, SIMONE
- Published
- 2022
- Full Text
- View/download PDF
15. P-109: ER-phagic control of lipid metabolism supports multiple myeloma cell survival
- Author
-
Oliva, Laura, Trudu, Matteo, Orfanelli, Ugo, Perini, Tommaso, Cassina, Laura, Zambroni, Desiree, Loffreda, Alessia, Raimondi, Andrea, Resnati, Massimo, Boletta, Alessandra, and Cenci, Simone
- Published
- 2022
- Full Text
- View/download PDF
16. Increased mitochondrial fragmentation in polycystic kidney disease acts as a modifier of disease progression.
- Author
-
Cassina, Laura, Chiaravalli, Marco, and Boletta, Alessandra
- Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenic disorder, characterized by bilateral renal cyst formation. Multiple pathways are de‐regulated in cystic epithelia offering good opportunities for therapy. Others and we have previously reported that metabolic reprogramming, including alterations of the TCA cycle, are prominent features of ADPKD. Several lines of evidence suggest that mitochondrial impairment might be responsible for the metabolic alterations. Here, we performed morphologic and morphometric evaluation of mitochondria by TEM in an orthologous mouse model of PKD caused by mutations in the Pkd1 gene (Ksp‐Cre;Pkd1flox/−). Furthermore, we measured mitochondrial respiration by COX and SDH enzymatic activity in situ. We found several alterations including reduced mitochondrial mass, altered structure and fragmentation of the mitochondrial network in cystic epithelia of Ksp‐Cre;Pkd1flox/− mice. At the molecular level, we found reduced expression of the pro‐fusion proteins OPA1 and MFN1 and up‐regulation of the pro‐fission protein DRP1. Importantly, administration of Mdivi‐1, which interferes with DRP1 rescuing mitochondrial fragmentation, significantly reduced kidney/body weight, cyst formation, and improved renal function in Ksp‐Cre;Pkd1flox/− mice. Our data indicate that impaired mitochondrial structure and function play a role in disease progression, and that their improvement can significantly modify the course of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. The Mitochondrial Protease AFG3L2 Is Essential for Axonal Development.
- Author
-
Maltecca, Francesca, Aghaie, Asadollah, Schroeder, David G., Cassina, Laura, Taylor, Benjamin A., Phillips, Sandra J., Malaguti, Mariachiara, Previtali, Stefano, Guénet, Jean-Louis, Quattrini, Angelo, Cox, Gregory A., and Casari, Giorgio
- Subjects
PROTEOLYTIC enzymes ,AXONS ,PROTEINS ,MITOCHONDRIA ,SPINAL cord ,NEURODEGENERATION - Abstract
The mitochondrial metalloprotease AFG3L2 assembles with the homologous protein paraplegin to form a supracomplex in charge of the essential protein quality control within mitochondria. Mutations of paraplegin cause a specific axonal degeneration of the upper motoneuron and, therefore, hereditary spastic paraplegia. Here we present two Afg3l2 murine models: a newly developed null and a spontaneous mutant that we found carrier of a missense mutation. Contrasting with the mild and late onset axonal degeneration of paraplegin-deficient mouse, Afg3l2 models display a marked impairment of axonal development with delayed myelination and poor axonal radial growth leading to lethality at P16. The increased severity of the Afg3l2 mutants is explained by two main molecular features that differentiate AFG3L2 from paraplegin: its higher neuronal expression and its versatile ability to support both hetero-oligomerization and homo-oligomerization. Our data assign to AFG3L2 a crucial role by linking mitochondrial metabolism and axonal development. Moreover, we propose AFG3L2 as an excellent candidate for motoneuron and cerebellar diseases with early onset unknown etiology. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
18. P-104: Targeting the mitochondrial protease CLPP in Multiple Myeloma.
- Author
-
Perini, Tommaso, Oliva, Laura, Materozzi, Maria, Cassina, Laura, Samur, Mehmet K., Orfanelli, Ugo, Milan, Enrico, Boletta, Alessandra, Munshi, Nikhil C., and Cenci, Simone
- Published
- 2021
- Full Text
- View/download PDF
19. The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity.
- Author
-
Cavalli, Giulio, Tengesdal, Isak W., Gresnigt, Mark, Nemkov, Travis, Arts, Rob J.W., Domínguez-Andrés, Jorge, Molteni, Raffaella, Stefanoni, Davide, Cantoni, Eleonora, Cassina, Laura, Giugliano, Silvia, Schraa, Kiki, Mills, Taylor S., Pietras, Eric M., Eisenmensser, Elan Z., Dagna, Lorenzo, Boletta, Alessandra, D'Alessandro, Angelo, Joosten, Leo A.B., and Netea, Mihai G.
- Abstract
Trained immunity (TI) is a de facto innate immune memory program induced in monocytes/macrophages by exposure to pathogens or vaccines, which evolved as protection against infections. TI is characterized by immunometabolic changes and histone post-translational modifications, which enhance production of pro-inflammatory cytokines. As aberrant activation of TI is implicated in inflammatory diseases, tight regulation is critical; however, the mechanisms responsible for this modulation remain elusive. Interleukin-37 (IL-37) is an anti-inflammatory cytokine that curbs inflammation and modulates metabolic pathways. In this study, we show that administration of recombinant IL-37 abrogates the protective effects of TI in vivo , as revealed by reduced host pro-inflammatory responses and survival to disseminated candidiasis. Mechanistically, IL-37 reverses the immunometabolic changes and histone post-translational modifications characteristic of TI in monocytes, thus suppressing cytokine production in response to infection. IL-37 thereby emerges as an inhibitor of TI and as a potential therapeutic target in immune-mediated pathologies. [Display omitted] • IL-37 counteracts the protective effects of trained immunity (TI) in vivo • IL-37 suppresses pro-inflammatory cytokine production • IL-37 reverses immunometabolic changes and histone modifications characteristic of TI Cavalli et al. demonstrate that the anti-inflammatory cytokine IL-37 regulates trained immunity (TI) in vivo. IL-37 reverses the immunometabolic changes and histone post-translational modifications underlying TI, thereby suppressing pro-inflammatory cytokine production. This regulatory role of IL-37 over myeloid-driven inflammation has implications for immune-mediated disorders and for host responses against pathogens. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Mitochondria remodeling during endometrial stromal cell decidualization.
- Author
-
Dalla Torre M, Pittari D, Boletta A, Cassina L, Sitia R, and Anelli T
- Subjects
- Female, Humans, Stromal Cells metabolism, Stromal Cells cytology, Mitochondria metabolism, Mitochondria genetics, Endometrium cytology, Endometrium metabolism, Decidua metabolism, Decidua cytology, Embryo Implantation genetics, Embryo Implantation physiology
- Abstract
Upon hormonal stimulation, uterine endometrial stromal cells undergo a dramatic morpho-functional metamorphosis that allows them to secrete large amounts of matrix proteins, cytokines, and growth factors. This step, known as decidualization, is crucial for embryo implantation. We previously demonstrated how the secretory pathway is remodelled during this process. Here we show that hormonal stimulation rapidly induces the expression of many mitochondrial genes, encoded in both the mitochondrial and the nuclear genomes. Altogether, the mitochondrial network quadruples its size and establishes more contacts with the ER. This new organization results in the increased respiratory capacity of decidualized cells. These findings reveal how achieving an efficient secretory phenotype requires a radical metabolic rewiring., (© 2024 Dalla Torre et al.)
- Published
- 2024
- Full Text
- View/download PDF
21. Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease.
- Author
-
Molteni R, Biavasco R, Stefanoni D, Nemkov T, Domínguez-Andrés J, Arts RJ, Merelli I, Mazza D, Zambrano S, Panigada M, Cantoni E, Tengesdal IW, Maksud P, Piras F, Cesana D, Cassina L, Distefano G, Loffreda A, Gnani D, De Luca G, Tomelleri A, Campochiaro C, Joosten LAB, Dinarello CA, Kajaste-Rudnitski A, Haroche J, Cardaci S, Cenci S, Dagna L, Doglioni C, Ferrarini M, Ferrero E, Boletta A, D'Alessandro A, Montini E, Netea MG, and Cavalli G
- Subjects
- Cells, Cultured, Epigenesis, Genetic, Erdheim-Chester Disease immunology, Erdheim-Chester Disease pathology, Humans, Immunity, Inflammation immunology, Inflammation pathology, Macrophages immunology, Macrophages metabolism, Macrophages pathology, Oncogenes, Point Mutation, Proto-Oncogene Proteins B-raf immunology, Erdheim-Chester Disease genetics, Inflammation genetics, Proto-Oncogene Proteins B-raf genetics
- Abstract
Trained immunity (TI) is a proinflammatory program induced in monocyte/macrophages upon sensing of specific pathogens and is characterized by immunometabolic and epigenetic changes that enhance cytokine production. Maladaptive activation of TI (ie, in the absence of infection) may result in detrimental inflammation and development of disease; however, the exact role and extent of inappropriate activation of TI in the pathogenesis of human diseases is undetermined. In this study, we uncovered the oncogene-induced, maladaptive induction of TI in the pathogenesis of a human inflammatory myeloid neoplasm (Erdheim-Chester disease, [ECD]), characterized by the BRAFV600E oncogenic mutation in monocyte/macrophages and excess cytokine production. Mechanistically, myeloid cells expressing BRAFV600E exhibit all molecular features of TI: activation of the AKT/mammalian target of rapamycin signaling axis; increased glycolysis, glutaminolysis, and cholesterol synthesis; epigenetic changes on promoters of genes encoding cytokines; and enhanced cytokine production leading to hyperinflammatory responses. In patients with ECD, effective therapeutic strategies combat this maladaptive TI phenotype; in addition, pharmacologic inhibition of immunometabolic changes underlying TI (ie, glycolysis) effectively dampens cytokine production by myeloid cells. This study revealed the deleterious potential of inappropriate activation of TI in the pathogenesis of human inflammatory myeloid neoplasms and the opportunity for inhibition of TI in conditions characterized by maladaptive myeloid-driven inflammation., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
22. Impaired flickering of the permeability transition pore causes SPG7 spastic paraplegia.
- Author
-
Sambri I, Massa F, Gullo F, Meneghini S, Cassina L, Carraro M, Dina G, Quattrini A, Patanella L, Carissimo A, Iuliano A, Santorelli F, Codazzi F, Grohovaz F, Bernardi P, Becchetti A, and Casari G
- Subjects
- ATPases Associated with Diverse Cellular Activities metabolism, Animals, Apoptosis genetics, Biological Transport, Calcium metabolism, Disease Models, Animal, Disease Susceptibility, Gene Editing, HEK293 Cells, Humans, Membrane Potential, Mitochondrial, Metalloendopeptidases metabolism, Mice, Mice, Knockout, Mitochondria genetics, Mitochondria metabolism, Mutation, Neurons metabolism, Phenotype, Reactive Oxygen Species metabolism, Sirtuin 3 metabolism, Spinal Cord metabolism, Spinal Cord pathology, Synaptic Vesicles metabolism, ATPases Associated with Diverse Cellular Activities genetics, Metalloendopeptidases genetics, Mitochondrial Permeability Transition Pore metabolism, Spastic Paraplegia, Hereditary genetics, Spastic Paraplegia, Hereditary metabolism
- Abstract
Background: Mutations of the mitochondrial protein paraplegin cause hereditary spastic paraplegia type 7 (SPG7), a so-far untreatable degenerative disease of the upper motoneuron with still undefined pathomechanism. The intermittent mitochondrial permeability transition pore (mPTP) opening, called flickering, is an essential process that operates to maintain mitochondrial homeostasis by reducing intra-matrix Ca
2+ and reactive oxygen species (ROS) concentration, and is critical for efficient synaptic function., Methods: We use a fluorescence-based approach to measure mPTP flickering in living cells and biochemical and molecular biology techniques to dissect the pathogenic mechanism of SPG7. In the SPG7 animal model we evaluate the potential improvement of the motor defect, neuroinflammation and neurodegeneration by means of an mPTP inducer, the benzodiazepine Bz-423., Findings: We demonstrate that paraplegin is required for efficient transient opening of the mPTP, that is impaired in both SPG7 patients-derived fibroblasts and primary neurons from Spg7-/- mice. We show that dysregulation of mPTP opening at the pre-synaptic terminal impairs neurotransmitter release leading to ineffective synaptic transmission. Lack of paraplegin impairs mPTP flickering by a mechanism involving increased expression and activity of sirtuin3, which promotes deacetylation of cyclophilin D, thus hampering mPTP opening. Pharmacological treatment with Bz-423, which bypasses the activity of CypD, normalizes synaptic transmission and rescues the motor impairment of the SPG7 mouse model., Interpretation: mPTP targeting opens a new avenue for the potential therapy of this form of spastic paraplegia., Funding: Telethon Foundation grant (TGMGCSBX16TT); Dept. of Defense, US Army, grant W81XWH-18-1-0001., Competing Interests: Declaration of Competing Interest We declare no conflict of interest., (Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
23. Metabolic reprogramming and the role of mitochondria in polycystic kidney disease.
- Author
-
Podrini C, Cassina L, and Boletta A
- Subjects
- Animals, Epigenesis, Genetic, Humans, Lipid Metabolism genetics, Models, Biological, Polycystic Kidney Diseases genetics, Polycystic Kidney Diseases therapy, Signal Transduction genetics, Mitochondria metabolism, Polycystic Kidney Diseases metabolism
- Abstract
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a slowly progressive disease characterized by the relentless growth of renal cysts throughout the life of affected individuals. Early evidence suggested that the epithelia lining the cysts share neoplastic features, leading to the definition of PKD as a "neoplasm in disguise". Recent work from our and other laboratories has identified a profound metabolic reprogramming in PKD, similar to the one reported in cancer and consistent with the reported increased proliferation. Multiple lines of evidence suggest that aerobic glycolysis (a Warburg-like effect) is present in the disease, along with other metabolic dysfunctions such as an increase in the pentose phosphate pathway, in glutamine anaplerosis and fatty acid biosynthesis, while fatty acid oxidation and oxidative phosphorylation (OXPHOS) are decreased. In addition to glutamine, other amino acid-related pathways appear altered, including asparagine and arginine. The precise origin of the metabolic alterations is not entirely clear, but two hypotheses can be formulated, not mutually exclusive. First, the polycystins have been recently shown to regulate directly mitochondrial function and structure either by regulating Ca
2+ uptake in mitochondria at the Mitochondria Associated Membranes (MAMs) of the Endoplasmic Reticulum, or by a direct translocation of a small fragment of the protein into the matrix of mitochondria. One alternative possibility is that metabolic and mitochondrial dysfunctions in ADPKD are secondary to the de-regulation of proliferation, driven by the multiple signaling pathways identified in the disease, which include mTORC1 and AMPK among the most relevant. While the precise mechanisms underlying these novel alterations identified in ADPKD will need further investigation, it is evident that they offer a great opportunity for novel interventions in the disease., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.